ShanghaiMay 20, 2026 /PRNewswire/ — As the medical aesthetics industry enters a new phase characterized by both intensified competition in a saturated market and stricter regulation, the entire sector is exploring how to seize transformation opportunities and return to the core of medical practice. On May 20, 2026, the “Endless Precision, Leading the Realm” 2026 Allergan Aesthetics Medical Aesthetics Summit and the Launch of Botox® for Forehead Lines Indication was held in Shanghai. The summit brought together leading domestic and international experts, industry leaders, and institutional representatives, focusing on the three core pillars of “Evidence-Based Standard Setting, Compliance and Co-Governance, and Refined Operations.” By implementing localized clinical standards, clarifying the boundaries of compliant operations, and releasing practical operational tools, the summit showcased Allergan Aesthetics’ systematic approach to driving the industry’s transformation from extensive expansion to high-quality development.
Scene from the 2026 Allergan Aesthetics Medical Aesthetics Summit and Launch of Botox® for Forehead Lines Indication
Evidence-Based Standard Setting: Building a Standardized Diagnosis and Treatment System for Upper Facial Rejuvenation
For a long time, upper facial rejuvenation treatments in China’s medical aesthetics industry have lacked standardized guidelines based on local population characteristics, with clinical practices largely relying on individual physician experience. Addressing this pain point, Professor Li Qin, President of the Facial Rejuvenation Branch of the Chinese Association of Plastics and Aesthetics, provided an in-depth interpretation of the “Expert Consensus on Upper Facial Rejuvenation Treatment for the Chinese Population” at the summit.
This consensus, based on the aesthetic characteristics and aging manifestations of the Chinese population’s upper face, systematically outlines the diagnostic and treatment logic for upper facial rejuvenation. It aims to shift the industry from experience-based “single-site wrinkle reduction” to a standardized system of “upper facial muscle balance management.” The establishment of this standard strongly echoes global clinical trends. At the summit, leading domestic and international experts shared findings from the international multi-center Phase IV study and real-world retrospective studies on Botox®. These studies provided robust international evidence-based medical support for combined multi-site upper facial treatments, covering dimensions such as naturalness, patient satisfaction, and benefits of combination therapy.
Professor Li Qin on-site interpreting the ‘Expert Consensus on Upper Facial Rejuvenation Treatment for the Chinese Population’
Professor Li Qin, President of the Facial Rejuvenation Branch of the Chinese Association of Plastics and Aesthetics, stated: “The facial anatomy and aesthetic needs of Chinese aesthetic seekers have unique local characteristics, yet there has been a lack of unified clinical standards. The ‘Expert Consensus on Upper Facial Rejuvenation Treatment for the Chinese Population’ fills this regulatory gap in the domestic field, providing a clear assessment system and operational pathway for clinical practice. The approval of the new indication further solidifies the evidence-based and compliance foundation for implementing the consensus. The two complement each other, ensuring that upper facial rejuvenation diagnosis and treatment are guided by evidence and grounded in standards.”
Compliance as a Safeguard: New Indications Build a ‘Moat’ for Industry Operations
As medical aesthetics regulation continues to tighten and become normalized, compliance has shifted from being a competitive advantage to the baseline for institutional survival. At the summit, several speakers noted that the successive approval of indication matrices essentially reflects the ongoing improvement of the industry’s evidence-based medicine system. A comprehensive portfolio of multiple indications not only provides physicians with more sufficient and authoritative compliant clinical diagnostic and treatment bases but also enriches and professionalizes the options for treatment plans, fundamentally raising the industry’s medical standards.
Roundtable discussion session: ‘Compliance as the Foundation, Growth for the Long Term: Exploring Sustainable Pathways for Medical Aesthetics Operations’
Professor Shi Bing, Chairman of the Plastic and Aesthetic Professional Committee of the Chinese Non-Government Medical Institutions Association, stated: “Compliance is the bottom line of clinical practice. The approval of the forehead lines indication further completes the compliant matrix of Botox® for the upper face, providing physicians with clear legal basis and authoritative evidence-based support. This makes diagnosis and treatment more standardized, offers greater protection for medical practice, and provides an institutional fulcrum for the industry to return to the essence of medicine.”
Professor Shi Bing speaking on-site
In response to the new trend of regulatory oversight shifting from backend remediation to front-end, full-process management, the approval of new indications has become a crucial product-level implementation of compliance construction in medical aesthetics. This not only provides institutions with compliant treatment tools, effectively reducing risks such as false and exaggerated advertising and off-label use, but also leverages full-chain traceability systems like “one person, one vial” and QR code tracking to build a strong foundation for authentic product assurance and support standardized operations. Only by forming a complete closed loop encompassing product compliance, clinical standards, and institutional operations can the industry truly be driven towards transparent and orderly development, making compliance a solid foundation for sustainable growth.
Lu Yiguang, Partner at Shanghai Llinks Law Offices, pointed out, “Against the backdrop of normalized regulation, off-label treatment is one of the biggest legal risks institutions face. Relying on the new Botox® forehead lines indication for standardized clinical application is a key step for institutions to build a compliance firewall and achieve stable operations.”
Refined Operations: From Price Competition to Value Delivery
Addressing the core operational pain points currently plaguing the medical aesthetics industry—oversupply, price wars, high traffic acquisition costs, and low customer retention—the summit saw Allergan Aesthetics, in collaboration with Roland Berger, release the “Botox® 2026 Operational Diagnosis White Paper.” This white paper offers practical solutions, providing a data-driven perspective for institutions to refine their operations. It proposes a systematic operational framework and actionable diagnostic indicators, helping institutions shift towards precise diagnosis, scientific management, and long-term growth.
Scene from the launch of the ‘Botox® 2026 Operational Diagnosis White Paper’
Leveraging the core findings of the white paper, the summit further proposed that institutions should focus on refined upper facial diagnosis and treatment and the optimization of the full-service experience. By integrating standardized diagnostic and treatment concepts into service details, institutions can build a healthy and sustainable product hierarchy, explore a second growth curve for long-term development, and achieve a transformation from “product sales” to “value delivery.” This involves visualizing and quantitatively assessing the value of diagnostic and treatment services as perceived by aesthetic seekers, thereby enhancing customer loyalty and lifetime value.
As a leading global biopharmaceutical company in medical aesthetics, Allergan Aesthetics remains rooted in medical science. It continues to help the industry navigate cycles through the upgrading of physician education systems, full-chain professional empowerment, and ecosystem-based collaborative support.
Qiu Hanhua, Vice President of Allergan Aesthetics and General Manager of China, stated: “Allergan Aesthetics unites industry forces with our original medical mission. By focusing on the three directions of evidence-based standard setting, compliance safeguarding, and refined operations, we provide actionable solutions for the industry. In the future, we will continue to partner with stakeholders to build a new, standardized, transparent, and value-sharing ecosystem for medical aesthetics.”